Use of miR-135b, miR-135a and their target gene AMOTL2 for medulloblastoma

摘要

The present invention provides a pharmaceutical for the prevention or treatment of medulloblastoma comprising miR-135b and miR-135a for predicting the possibility of metastasis or recurrence of medulloblastoma, the miRNA target gene AMOTL2 for predicting the prognosis, and an inhibitor of the miRNA as active ingredients When using the biomarker for predicting metastasis or recurrence of medulloblastoma and the biomarker for predicting the prognosis according to the present invention as a pharmaceutical composition, etc., the expression level of miR-135b or miR-135a in treating an incurable medulloblastoma patient By measuring , the possibility of tumor metastasis and recurrence can be predicted, and the prognosis of a patient can be predicted by measuring the expression level of AMOTL2, a target gene of the miRNA. Furthermore, by artificially suppressing the expression of the miRNA to induce an increase in the expression of AMOTL2, it is expected to be able to effectively prevent and treat medulloblastoma.